Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	alpha-L-arabinofuranosidase activity	OTOGL OTOG	5.90e-06	2	49	2	GO:0046556
GeneOntologyMolecularFunction	voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	KCNC1 KCNC4 SCN2A	9.22e-06	17	49	3	GO:0099508
GeneOntologyBiologicalProcess	arabinose metabolic process	OTOGL OTOG	5.30e-06	2	48	2	GO:0019566
GeneOntologyBiologicalProcess	vibrational conductance of sound to the inner ear	OTOGL OTOG	5.30e-06	2	48	2	GO:0055127
GeneOntologyBiologicalProcess	L-arabinose metabolic process	OTOGL OTOG	5.30e-06	2	48	2	GO:0046373
GeneOntologyBiologicalProcess	trans-synaptic signaling, modulating synaptic transmission	LPA PLG GRM5	2.96e-05	26	48	3	GO:0099550
GeneOntologyBiologicalProcess	positive regulation of fibrinolysis	LPA PLG	5.28e-05	5	48	2	GO:0051919
GeneOntologyBiologicalProcess	trans-synaptic signaling by BDNF, modulating synaptic transmission	LPA PLG	1.11e-04	7	48	2	GO:0099183
GeneOntologyBiologicalProcess	trans-synaptic signaling by BDNF	LPA PLG	1.47e-04	8	48	2	GO:0099191
GeneOntologyCellularComponent	cell surface	LIFR ITGBL1 KCNC1 PTPRJ KCNC4 ASGR1 LPA PLG LY75 KLRB1	2.13e-04	1111	49	10	GO:0009986
MousePheno	abnormal mammary gland connective tissue morphology	LPA PLG	9.68e-06	2	44	2	MP:0009507
MousePheno	esophageal ulcer	LPA PLG	9.68e-06	2	44	2	MP:0004547
MousePheno	duodenal ulcer	LPA PLG	9.68e-06	2	44	2	MP:0003273
MousePheno	perianal ulcer	LPA PLG	9.68e-06	2	44	2	MP:0005035
MousePheno	ectropion	LPA PLG	9.68e-06	2	44	2	MP:0006164
MousePheno	absent cornea epithelium	LPA PLG	2.90e-05	3	44	2	MP:0020856
MousePheno	increased circulating fibrinogen level	LPA PLG	5.79e-05	4	44	2	MP:0012331
MousePheno	proctitis	LPA PLG	5.79e-05	4	44	2	MP:0003305
MousePheno	hepatic necrosis	JARID2 NEURL3 LPA PLG	1.08e-04	79	44	4	MP:0001654
MousePheno	gastric ulcer	LPA PLG	1.44e-04	6	44	2	MP:0003282
MousePheno	increased acute phase protein level	LPA PLG	2.01e-04	7	44	2	MP:0014499
MousePheno	abnormal conjunctival epithelium morphology	LPA PLG	2.01e-04	7	44	2	MP:0004481
MousePheno	venoocclusion	LPA PLG	2.01e-04	7	44	2	MP:0006137
MousePheno	peptic ulcer	LPA PLG	2.01e-04	7	44	2	MP:0003301
MousePheno	decreased keratinocyte migration	LPA PLG	2.68e-04	8	44	2	MP:0012194
MousePheno	abnormal circulating fibrinogen level	LPA PLG	2.68e-04	8	44	2	MP:0010213
MousePheno	decreased susceptibility to induced choroidal neovascularization	LPA PLG	4.29e-04	10	44	2	MP:0003434
MousePheno	abnormal kidney thrombosis	LPA PLG	4.29e-04	10	44	2	MP:0011507
MousePheno	abnormal keratinocyte migration	LPA PLG	5.23e-04	11	44	2	MP:0012192
MousePheno	abnormal optic choroid morphology	LPA INTS15 PLG	5.77e-04	52	44	3	MP:0005098
MousePheno	distended pericardium	JARID2 PTPRJ PAXIP1	6.81e-04	55	44	3	MP:0000292
MousePheno	abnormal anus morphology	LPA PLG	7.39e-04	13	44	2	MP:0005034
MousePheno	abnormal conjunctiva morphology	LPA PLG	7.39e-04	13	44	2	MP:0001310
Domain	Channel_four-helix_dom	KCNC1 KCNC4 SCN2A SCN4A	1.26e-05	57	47	4	IPR027359
Domain	-	KCNC1 KCNC4 SCN2A SCN4A	1.26e-05	57	47	4	1.20.120.350
Domain	K_chnl_volt-dep_Kv3	KCNC1 KCNC4	3.71e-05	4	47	2	IPR003974
Domain	Kringle-like	LPA PLG LY75	7.04e-05	32	47	3	IPR013806
Domain	BTG_2	BTG3 BTG4	9.24e-05	6	47	2	PS01203
Domain	BTG_1	BTG3 BTG4	9.24e-05	6	47	2	PS00960
Domain	Anti_prolifrtn	BTG3 BTG4	9.24e-05	6	47	2	IPR002087
Domain	btg1	BTG3 BTG4	9.24e-05	6	47	2	SM00099
Domain	BTG	BTG3 BTG4	9.24e-05	6	47	2	PF07742
Domain	Ion_trans_dom	KCNC1 KCNC4 SCN2A SCN4A	1.92e-04	114	47	4	IPR005821
Domain	Ion_trans	KCNC1 KCNC4 SCN2A SCN4A	1.92e-04	114	47	4	PF00520
Domain	-	MEGF8 ENC1 IPP	2.39e-04	48	47	3	2.120.10.80
Domain	Na_channel_asu	SCN2A SCN4A	2.75e-04	10	47	2	IPR001696
Domain	Na_trans_assoc	SCN2A SCN4A	2.75e-04	10	47	2	IPR010526
Domain	Na_trans_assoc	SCN2A SCN4A	2.75e-04	10	47	2	PF06512
Domain	Kelch-typ_b-propeller	MEGF8 ENC1 IPP	3.57e-04	55	47	3	IPR015915
Domain	TIL	MUC19 OTOG	4.03e-04	12	47	2	PF01826
Domain	C8	MUC19 OTOG	4.03e-04	12	47	2	PF08742
Domain	Gal_Oxase/kelch_b-propeller	MEGF8 ENC1 IPP	4.40e-04	59	47	3	IPR011043
Domain	Unchr_dom_Cys-rich	MUC19 OTOG	4.75e-04	13	47	2	IPR014853
Domain	C8	MUC19 OTOG	4.75e-04	13	47	2	SM00832
Domain	TIL_dom	MUC19 OTOG	5.53e-04	14	47	2	IPR002919
Domain	Kelch_1	MEGF8 ENC1 IPP	7.26e-04	70	47	3	PF01344
Domain	Kelch_1	MEGF8 ENC1 IPP	7.26e-04	70	47	3	IPR006652
Domain	VWD	MUC19 OTOG	7.27e-04	16	47	2	SM00216
Domain	VWF_type-D	MUC19 OTOG	7.27e-04	16	47	2	IPR001846
Domain	VWFD	MUC19 OTOG	7.27e-04	16	47	2	PS51233
Domain	VWD	MUC19 OTOG	7.27e-04	16	47	2	PF00094
Domain	Kringle	LPA PLG	8.23e-04	17	47	2	IPR000001
Domain	Kringle_CS	LPA PLG	8.23e-04	17	47	2	IPR018056
Domain	KRINGLE_2	LPA PLG	8.23e-04	17	47	2	PS50070
Domain	Kringle	LPA PLG	8.23e-04	17	47	2	PF00051
Domain	KRINGLE_1	LPA PLG	8.23e-04	17	47	2	PS00021
Domain	KR	LPA PLG	8.23e-04	17	47	2	SM00130
Domain	VWC_out	MUC19 OTOG	1.03e-03	19	47	2	SM00215
Domain	C_TYPE_LECTIN_1	ASGR1 LY75 KLRB1	1.07e-03	80	47	3	PS00615
Domain	BTB	KCNC1 KCNC4 ENC1 IPP	1.08e-03	180	47	4	SM00225
Domain	BTB/POZ_dom	KCNC1 KCNC4 ENC1 IPP	1.19e-03	185	47	4	IPR000210
Domain	Lectin_C	ASGR1 LY75 KLRB1	1.23e-03	84	47	3	PF00059
Domain	CLECT	ASGR1 LY75 KLRB1	1.23e-03	84	47	3	SM00034
Domain	C_TYPE_LECTIN_2	ASGR1 LY75 KLRB1	1.28e-03	85	47	3	PS50041
Domain	SKP1/BTB/POZ	KCNC1 KCNC4 ENC1 IPP	1.29e-03	189	47	4	IPR011333
Domain	C-type_lectin-like	ASGR1 LY75 KLRB1	1.32e-03	86	47	3	IPR001304
Domain	CT	MUC19 OTOG	1.39e-03	22	47	2	SM00041
Domain	Cys_knot_C	MUC19 OTOG	1.79e-03	25	47	2	IPR006207
Domain	CTCK_2	MUC19 OTOG	1.79e-03	25	47	2	PS01225
Domain	C-type_lectin-like/link	ASGR1 LY75 KLRB1	1.98e-03	99	47	3	IPR016186
Domain	K_chnl_volt-dep_Kv	KCNC1 KCNC4	2.09e-03	27	47	2	IPR003968
Domain	ZnF_U1	ZFHX4 ZFHX3	2.41e-03	29	47	2	SM00451
Domain	Znf_U1	ZFHX4 ZFHX3	2.41e-03	29	47	2	IPR003604
Domain	CTDL_fold	ASGR1 LY75 KLRB1	2.47e-03	107	47	3	IPR016187
Domain	VG_K_chnl	KCNC1 KCNC4	3.11e-03	33	47	2	IPR028325
Domain	VWF_dom	MUC19 OTOG	5.01e-03	42	47	2	IPR001007
Domain	BTB-kelch_protein	ENC1 IPP	5.24e-03	43	47	2	IPR017096
Domain	C-type_lectin_CS	ASGR1 LY75	5.24e-03	43	47	2	IPR018378
Domain	PSI	MEGF8 SEMA3E	5.48e-03	44	47	2	IPR016201
Domain	PSI	MEGF8 SEMA3E	5.98e-03	46	47	2	SM00423
Domain	CUB	LRP12 MEGF8	6.76e-03	49	47	2	PF00431
Domain	CUB	LRP12 MEGF8	7.03e-03	50	47	2	SM00042
Pubmed	Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes.	LPA PLG LPAL2	1.05e-08	4	49	3	21900290
Pubmed	Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function.	LPA PLG	1.94e-06	2	49	2	21239499
Pubmed	Short-term inhibition of fibrinolytic system restores locomotor function after spinal cord injury in mice.	LPA PLG	1.94e-06	2	49	2	31690812
Pubmed	Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.	LPA PLG	1.94e-06	2	49	2	30254165
Pubmed	Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.	LPA PLG	1.94e-06	2	49	2	10642175
Pubmed	Plasminogen mRNA induction in the mouse brain after kainate excitation: codistribution with plasminogen activator inhibitor-2 (PAI-2) mRNA.	LPA PLG	1.94e-06	2	49	2	12225871
Pubmed	Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice.	LPA PLG	1.94e-06	2	49	2	9770530
Pubmed	Plasminogen deficiency exacerbates skeletal muscle loss during mechanical unloading in developing mice.	LPA PLG	1.94e-06	2	49	2	38328826
Pubmed	The mouse ZFH-4 protein contains four homeodomains and twenty-two zinc fingers.	ZFHX4 ZFHX3	1.94e-06	2	49	2	10873665
Pubmed	Reduced transplant arteriosclerosis in plasminogen-deficient mice.	LPA PLG	1.94e-06	2	49	2	9819364
Pubmed	Plasminogen activation is required for the development of radiation-induced dermatitis.	LPA PLG	1.94e-06	2	49	2	30323258
Pubmed	Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression.	LPA PLG	1.94e-06	2	49	2	37971174
Pubmed	The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.	LPA PLG	1.94e-06	2	49	2	9884337
Pubmed	Persistent corneal haze after excimer laser photokeratectomy in plasminogen-deficient mice.	LPA PLG	1.94e-06	2	49	2	10634603
Pubmed	Colonic Lesions, Cytokine Profiles, and Gut Microbiota in Plasminogen-Deficient Mice.	LPA PLG	1.94e-06	2	49	2	26473342
Pubmed	Thrombomodulin functions as a plasminogen receptor to modulate angiogenesis.	LPA PLG	1.94e-06	2	49	2	23943648
Pubmed	In vivo plasminogen deficiency reduces fat accumulation.	LPA PLG	1.94e-06	2	49	2	12083480
Pubmed	Polymorphonuclear leukocyte phagocytic function increases in plasminogen knockout mice.	LPA PLG	1.94e-06	2	49	2	18420257
Pubmed	Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.	LPA PLG	1.94e-06	2	49	2	7705657
Pubmed	Nonfibrinolytic functions of plasminogen.	LPA PLG	1.94e-06	2	49	2	10816371
Pubmed	Nucleocytoplasmic coagulation: an injury-induced aggregation event that disulfide crosslinks proteins and facilitates their removal by plasmin.	LPA PLG	1.94e-06	2	49	2	23041318
Pubmed	Plasminogen alleles influence susceptibility to invasive aspergillosis.	LPA PLG	1.94e-06	2	49	2	18566672
Pubmed	A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis.	LPA PLG	1.94e-06	2	49	2	19752236
Pubmed	Plasminogen is a critical regulator of cutaneous wound healing.	LPA PLG	1.94e-06	2	49	2	26791370
Pubmed	Selection of mutant µplasmin for amyloid-β cleavage in vivo.	LPA PLG	1.94e-06	2	49	2	32694536
Pubmed	Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.	LPA PLG	1.94e-06	2	49	2	7525077
Pubmed	Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site.	LPA PLG	1.94e-06	2	49	2	6216475
Pubmed	Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.	LPA PLG	1.94e-06	2	49	2	16052596
Pubmed	Functional corpora lutea are formed in matrix metalloproteinase inhibitor-treated plasminogen-deficient mice.	LPA PLG	1.94e-06	2	49	2	17122079
Pubmed	The generation and characterization of mice expressing a plasmin-inactivating active site mutation.	LPA PLG	1.94e-06	2	49	2	20653841
Pubmed	Influence of plasminogen deficiency on the contribution of polymorphonuclear leucocytes to fibrin/ogenolysis: studies in plasminogen knock-out mice.	LPA PLG	1.94e-06	2	49	2	12428098
Pubmed	Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus.	LPA PLG	1.94e-06	2	49	2	20440070
Pubmed	Role of plasminogen in propagation of scrapie.	LPA PLG	1.94e-06	2	49	2	16103174
Pubmed	Plasminogen deficiency causes reduced corticospinal axonal plasticity and functional recovery after stroke in mice.	LPA PLG	1.94e-06	2	49	2	24732409
Pubmed	Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques.	LPA PLG	1.94e-06	2	49	2	21300353
Pubmed	A central role for plasminogen in the inflammatory response to biomaterials.	LPA PLG	1.94e-06	2	49	2	15456492
Pubmed	Plasminogen promotes macrophage phagocytosis in mice.	LPA PLG	1.94e-06	2	49	2	24876560
Pubmed	Plasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in mice.	LPA PLG	1.94e-06	2	49	2	24574269
Pubmed	Spontaneous development of otitis media in plasminogen-deficient mice.	LPA PLG	1.94e-06	2	49	2	16956791
Pubmed	Staphylococcus aureus manganese transport protein C (MntC) is an extracellular matrix- and plasminogen-binding protein.	LPA PLG	1.94e-06	2	49	2	25409527
Pubmed	Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation.	LPA PLG	1.94e-06	2	49	2	15737740
Pubmed	Selective behaviors altered in plasminogen-deficient mice are reconstituted with intracerebroventricular injection of plasminogen.	LPA PLG	1.94e-06	2	49	2	11306011
Pubmed	The mouse plasminogen locus maps to the recombination breakpoints of the tLub2 and TtOrl partial t haplotypes but is not at the tw73 locus.	LPA PLG	1.94e-06	2	49	2	1543918
Pubmed	Localization of regulatory elements mediating constitutive and cytokine-stimulated plasminogen gene expression.	LPA PLG	1.94e-06	2	49	2	12149246
Pubmed	Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen.	LPA PLG	1.94e-06	2	49	2	8704243
Pubmed	Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis.	LPA PLG	1.94e-06	2	49	2	22056679
Pubmed	Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals.	LPA PLG	1.94e-06	2	49	2	17267741
Pubmed	Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis.	LPA PLG	1.94e-06	2	49	2	18311818
Pubmed	Localization of plasminogen in mouse hippocampus, cerebral cortex, and hypothalamus.	LPA PLG	1.94e-06	2	49	2	21190118
Pubmed	The lack of binding of VEK-30, an internal peptide from the group A streptococcal M-like protein, PAM, to murine plasminogen is due to two amino acid replacements in the plasminogen kringle-2 domain.	LPA PLG	1.94e-06	2	49	2	18039665
Pubmed	Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.	LPA PLG	1.94e-06	2	49	2	9671388
Pubmed	A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response.	LPA PLG	1.94e-06	2	49	2	18997104
Pubmed	Growth and behavioral development in plasminogen gene-targeted mice.	LPA PLG	1.94e-06	2	49	2	10885855
Pubmed	Similar phenotypes caused by mutations in OTOG and OTOGL.	OTOGL OTOG	1.94e-06	2	49	2	24378291
Pubmed	Plasmin promotes foam cell formation by increasing macrophage catabolism of aggregated low-density lipoprotein.	LPA PLG	1.94e-06	2	49	2	23702659
Pubmed	Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells.	LPA PLG	1.94e-06	2	49	2	29990619
Pubmed	Cellular density regulation of plasminogen gene expression in mouse hepatocytes.	LPA PLG	1.94e-06	2	49	2	12559391
Pubmed	Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector.	LPA PLG	1.94e-06	2	49	2	17293777
Pubmed	Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.	LPA PLG	1.94e-06	2	49	2	27319402
Pubmed	Plasminogen is a critical host pathogenicity factor for group A streptococcal infection.	LPA PLG	1.94e-06	2	49	2	15333838
Pubmed	Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen.	LPA PLG	1.94e-06	2	49	2	16150044
Pubmed	Plasminogen has a broad extrahepatic distribution.	LPA PLG	1.94e-06	2	49	2	11916082
Pubmed	Plasminogen plays a crucial role in bone repair.	LPA PLG	1.94e-06	2	49	2	23456978
Pubmed	Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction.	LPA PLG	1.94e-06	2	49	2	10854210
Pubmed	Unaltered prion protein cleavage in plasminogen-deficient mice.	LPA PLG	1.94e-06	2	49	2	16543819
Pubmed	Essential role of DNA-PKcs and plasminogen for the development of doxorubicin-induced glomerular injury in mice.	LPA PLG	1.94e-06	2	49	2	34423816
Pubmed	Delayed invasion of the kidney and brain by Borrelia crocidurae in plasminogen-deficient mice.	LPA PLG	1.94e-06	2	49	2	11500461
Pubmed	Gender affects skin wound healing in plasminogen deficient mice.	LPA PLG	1.94e-06	2	49	2	23527289
Pubmed	Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation.	LPA PLG	1.94e-06	2	49	2	22079981
Pubmed	Growth of human squamous cell carcinoma xenografts in mice is inhibited by local angiostatin gene therapy.	LPA PLG	1.94e-06	2	49	2	12167431
Pubmed	Impaired wound healing in mice with a disrupted plasminogen gene.	LPA PLG	1.94e-06	2	49	2	8612226
Pubmed	Role of plasminogen activation in neuronal organization and survival.	LPA PLG	1.94e-06	2	49	2	19683575
Pubmed	Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice.	LPA PLG	1.94e-06	2	49	2	9490683
Pubmed	Ovulation in plasminogen-deficient mice.	LPA PLG	1.94e-06	2	49	2	10537128
Pubmed	Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.	LPA PLG	1.94e-06	2	49	2	23555246
Pubmed	Kringle 5 of human plasminogen suppresses hepatocellular carcinoma growth both in grafted and xenografted mice by anti-angiogenic activity.	LPA PLG	1.94e-06	2	49	2	16481742
Pubmed	Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation.	LPA PLG	1.94e-06	2	49	2	18983515
Pubmed	Binding of plasminogen to hepatocytes isolated from injured mouse liver and nonparenchymal-cell-dependent proliferation of hepatocytes.	LPA PLG	1.94e-06	2	49	2	18685433
Pubmed	Plasminogen mediates communication between the peripheral and central immune systems during systemic immune challenge with lipopolysaccharide.	LPA PLG	1.94e-06	2	49	2	31462325
Pubmed	Plasminogen Regulates Fracture Repair by Promoting the Functions of Periosteal Mesenchymal Progenitors.	LPA PLG	1.94e-06	2	49	2	34378815
Pubmed	Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice.	LPA PLG	1.94e-06	2	49	2	11848464
Pubmed	Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.	LPA PLG	1.94e-06	2	49	2	7586361
Pubmed	Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis.	LPA PLG	1.94e-06	2	49	2	9242524
Pubmed	Functional Variant in the SLC22A3-LPAL2-LPA Gene Cluster Contributes to the Severity of Coronary Artery Disease.	LPA LPAL2	5.83e-06	3	49	2	27417586
Pubmed	Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice.	LPA PLG	5.83e-06	3	49	2	16818777
Pubmed	Skin wound healing in MMP2-deficient and MMP2 / plasminogen double-deficient mice.	LPA PLG	5.83e-06	3	49	2	20163454
Pubmed	Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells.	LPA PLG	5.83e-06	3	49	2	19273908
Pubmed	Lack of association between four SNPs in the SLC22A3-LPAL2-LPA gene cluster and coronary artery disease in a Chinese Han population: a case control study.	LPA LPAL2	5.83e-06	3	49	2	23036009
Pubmed	Ligneous conjunctivitis in plasminogen-deficient mice.	LPA PLG	5.83e-06	3	49	2	9473227
Pubmed	Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis.	LPA PLG	5.83e-06	3	49	2	17988229
Pubmed	Genetic background determines response to hemostasis and thrombosis.	LPA PLG	5.83e-06	3	49	2	17022820
Pubmed	Plasminogen binds to disease-associated prion protein of multiple species.	LPA PLG	5.83e-06	3	49	2	11438139
Pubmed	Lactational competence and involution of the mouse mammary gland require plasminogen.	LPA PLG	5.83e-06	3	49	2	11003846
Pubmed	Plasminogen regulates pro-opiomelanocortin processing.	LPA PLG	5.83e-06	3	49	2	15099286
Pubmed	Pneumococcal phosphoglycerate kinase interacts with plasminogen and its tissue activator.	LPA PLG	5.83e-06	3	49	2	24196407
Pubmed	Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice.	LPA PLG	5.83e-06	3	49	2	15364412
Pubmed	Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1.	LPA PLG	5.83e-06	3	49	2	28320709
Pubmed	Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice.	LPA PLG	5.83e-06	3	49	2	17722076
Pubmed	Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT.	LPA PLG	5.83e-06	3	49	2	21940822
Pubmed	Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification.	LPA PLG	5.83e-06	3	49	2	26214526
Interaction	FEV interactions	ZFHX4 PAXIP1 BEND3 ZFHX3 TAF2 ZMYM3	9.46e-06	203	49	6	int:FEV
Cytoband	Ensembl 112 genes in cytogenetic band chr6q26	LPA PLG	1.33e-04	16	49	2	chr6q26
Cytoband	6q26	LPA PLG	1.69e-04	18	49	2	6q26
Cytoband	Ensembl 112 genes in cytogenetic band chr11p15	KCNC1 SBF2 TSPAN4 OTOG	3.08e-03	564	49	4	chr11p15
GeneFamily	BTG/Tob family	BTG3 BTG4	5.75e-05	6	36	2	1309
GeneFamily	C-type lectin domain family	ASGR1 LY75 KLRB1	1.11e-04	47	36	3	494
GeneFamily	Sodium voltage-gated channel alpha subunits	SCN2A SCN4A	1.38e-04	9	36	2	1203
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	ZFHX4 ZFHX3	3.98e-04	15	36	2	529
GeneFamily	Potassium voltage-gated channels	KCNC1 KCNC4	2.87e-03	40	36	2	274
GeneFamily	Kelch like\|BTB domain containing	ENC1 IPP	3.16e-03	42	36	2	617
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	LIFR PTPRJ LY75 KLRB1	7.54e-03	394	36	4	471
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HNBGABA	ZFHX4 KCNC1 SCN2A ENC1 MUC19 ZFHX3 THSD7B GRM5 SEMA3E	5.37e-06	703	49	9	M39070
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HNBML5	ZFHX4 KCNC1 PLPP2 SCN2A ENC1 MUC19 ZFHX3	2.39e-05	465	49	7	M39066
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HGABA	LRP12 ZFHX4 KCNC1 SCN2A SBF2 ENC1 MUC19 ZFHX3 GRM5 SEMA3E	3.15e-05	1106	49	10	M39071
Coexpression	RANKIN_ANGIOGENIC_TARGETS_OF_VHL_HIF2A_UP	LPA PLG	5.11e-05	6	49	2	MM555
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L2/3_IT-L2/3_IT_VISp_Agmat\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	LIFR ZFHX4 ENC1 BTG3	2.61e-05	156	49	4	09e0702400570089d9012dcf94dfb4827c97e49d
ToppCell	5'-GW_trimst-2-SmallIntestine-Epithelial-Tuft-related-Tuft\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PTPRJ PLPP2 ZFHX3 PLG	2.95e-05	161	49	4	f5df8c6a340d5026726804b103e32137f363ca40
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L2/3_IT\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	LIFR ZFHX4 ENC1 BTG3	2.95e-05	161	49	4	e3327c296d48e821004e61a573abb75624a6f040
ToppCell	Adult-Mesenchymal-chondrocyte-D175\|Adult / Lineage, Cell type, age group and donor	ZFHX4 KCNC4 TSPAN4 PKDCC	3.49e-05	168	49	4	14071b961c9bdb54a8259b12a88237b802cbde36
ToppCell	facs-Heart-RV-18m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KCNC1 PLPP2 LY75 SEMA3E	3.82e-05	172	49	4	a26a73c41e5a05c9dd47a99f3320295f684c5e54
ToppCell	facs-Trachea-24m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l6-17\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SCN2A IPP PAN2 THSD7B	4.27e-05	177	49	4	8abdf1d970b2f15e17e185f3e612dd5065c88757
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZFHX4 OTOGL SCN2A OTOG	4.97e-05	184	49	4	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZFHX4 OTOGL SCN2A OTOG	4.97e-05	184	49	4	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZFHX4 OTOGL SCN2A OTOG	4.97e-05	184	49	4	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	facs-Skin-nan-24m-Mesenchymal\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGBL1 ZFHX4 TSPAN4 PKDCC	5.07e-05	185	49	4	8433a337625ff8398520e223ef92bf9bb0beb14c
ToppCell	facs-Skin-nan-24m-Mesenchymal-fibroblast\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGBL1 ZFHX4 TSPAN4 PKDCC	5.07e-05	185	49	4	049d793d043d5d434f143025de49dd210d18756c
ToppCell	3'-Child04-06-SmallIntestine-Epithelial-Tuft-related-Tuft\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PTPRJ PLPP2 LPA ZFHX3	5.07e-05	185	49	4	686ed7550c6acd18e71e0076936ec5b07389adbd
ToppCell	facs-Skin-nan-24m-Mesenchymal-nan\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ITGBL1 ZFHX4 TSPAN4 PKDCC	5.07e-05	185	49	4	63200c42565eea596f9b00728e70e544b8d50a7f
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_Arw_fibro_(16)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	LPA ZFHX3 PLG SEMA3E	5.18e-05	186	49	4	4d68ee3d32f7ef884faf402ef92b31b0eb4656f1
ToppCell	Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte\|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	OTOGL SCN2A MUC19 ZFHX3	5.18e-05	186	49	4	23b8d51d20b05795a73892d3e20e0f9b6a207820
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Neuronal-ventral_progenitors_and_neurons_1\|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type.	ZFHX4 SCN2A ZFHX3 GRM5	5.63e-05	190	49	4	6e92c78799f34b31d098854503c796edb0dc7f80
ToppCell	5'-Adult-LargeIntestine-Epithelial-Tuft-related-Tuft\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PTPRJ LPA ENC1 ZFHX3	5.74e-05	191	49	4	54f07e4de61735051498846afb44b1798bed8144
ToppCell	Parenchyma_Control_(B.)-Epithelial-TX-Basal_1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	NEURL3 PLPP2 GRM5 BTG4	6.47e-05	197	49	4	2701864e49878c5f323f5133e2c4b0a5a7fff7f5
ToppCell	Lung_Parenchyma-Control-Epithelial-Epithelial-Basal_1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	NEURL3 PLPP2 GRM5 BTG4	6.47e-05	197	49	4	751f19b00f92e1334f653b870d3f7c0c149ff41a
ToppCell	Control-gd_T\|Control / Disease condition and Cell class	PLPP2 ENC1 BTG3 KLRB1	6.47e-05	197	49	4	000b3269c152d80527b5ad9412dd4e71b73ef1ca
ToppCell	Lung_Parenchyma-Control-Epithelial-Epithelial-Basal_1-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NEURL3 PLPP2 GRM5 BTG4	6.47e-05	197	49	4	58d809ccb8cc4b1e76acf0b8f996cd0e2637290c
ToppCell	Tracheal-NucSeq-Epithelial-Epi_submucosal-gland-SMG_Serous\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	LIFR NEURL3 PTPRJ PKDCC	6.86e-05	200	49	4	7c2d499af60654b7b28f172ac2c914ad49fb74b4
Drug	mu-conotoxin KIIIA, Conus kinoshitai	SCN2A SCN4A	4.54e-06	2	49	2	ctd:C502265
Drug	Aminocaproic Acid	LPA PLG	1.36e-05	3	49	2	DB00513
Drug	1-chloro-1,2,2-trifluorocyclobutane	SCN2A SCN4A GRM5	1.84e-05	24	49	3	CID000079091
Drug	probucol	NPC1 LRP12 LPA PLG LPAL2	2.54e-05	162	49	5	CID000004912
Drug	Fospropofol	SCN2A SCN4A	2.71e-05	4	49	2	DB06716
Drug	Propofol	SCN2A SCN4A	2.71e-05	4	49	2	DB00818
Disease	chronic kidney disease, APOL1 risk genotype carrier status	OTOGL LPA PLG	4.03e-08	5	48	3	EFO_0003884, EFO_0009324
Disease	lipoprotein A measurement, apolipoprotein A 1 measurement	LPA PLG LPAL2	1.41e-07	7	48	3	EFO_0004614, EFO_0006925
Disease	chylomicron measurement, triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement	ASGR1 LPA PLG LPAL2	2.76e-07	34	48	4	EFO_0008317, EFO_0008596, EFO_0020947
Disease	total lipids in very large HDL measurement	ASGR1 LPA PLG LPAL2	4.12e-06	66	48	4	EFO_0022312
Disease	phospholipids in very large HDL measurement	ASGR1 LPA PLG LPAL2	4.12e-06	66	48	4	EFO_0022298
Disease	cholesteryl ester measurement, high density lipoprotein cholesterol measurement	ASGR1 LPA SBF2 PLG MAPKBP1 LPAL2	1.12e-05	312	48	6	EFO_0004612, EFO_0010351
Disease	total cholesterol measurement, high density lipoprotein cholesterol measurement	ASGR1 LPA SBF2 PLG MAPKBP1 LPAL2	1.19e-05	315	48	6	EFO_0004574, EFO_0004612
Disease	free cholesterol measurement, high density lipoprotein cholesterol measurement	ASGR1 LPA SBF2 PLG MAPKBP1 LPAL2	1.19e-05	315	48	6	EFO_0004612, EFO_0008591
Disease	lipid measurement, high density lipoprotein cholesterol measurement	ASGR1 LPA SBF2 PLG MAPKBP1 LPAL2	1.54e-05	330	48	6	EFO_0004529, EFO_0004612
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio	LPA PLG LPAL2	2.33e-05	34	48	3	EFO_0008317, EFO_0008596, EFO_0020944
Disease	plasma plasminogen measurement	LPA PLG	2.58e-05	5	48	2	EFO_0006309
Disease	cholesterol in small HDL measurement	ASGR1 SBF2 LPAL2	2.78e-05	36	48	3	EFO_0022226
Disease	triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement	ASGR1 LPA HELZ2 PLG LPAL2	3.23e-05	225	48	5	EFO_0008317, EFO_0020947
Disease	angiostatin measurement	LPA PLG	3.87e-05	6	48	2	EFO_0008024
Disease	cholesteryl esters to total lipids in small LDL percentage	LPA PLG LPAL2	4.44e-05	42	48	3	EFO_0022255
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio	LPA PLG LPAL2	5.84e-05	46	48	3	EFO_0008317, EFO_0008596, EFO_0020943
Disease	cholesteryl ester measurement	ASGR1 LPA SBF2 PLG LPAL2	6.08e-05	257	48	5	EFO_0010351
Disease	very low density lipoprotein particle size measurement	ASGR1 LPA PLG LPAL2	6.58e-05	133	48	4	EFO_0008594
Disease	heart failure, body fat percentage	NPC1 LPA	7.21e-05	8	48	2	EFO_0003144, EFO_0007800
Disease	polyunsaturated fatty acids to total fatty acids percentage	LPA PLG LPAL2	7.50e-05	50	48	3	EFO_0022303
Disease	Vertigo	LRP12 OTOGL GRM5 OTOG	7.81e-05	139	48	4	HP_0002321
Disease	polyunsaturated fatty acids to monounsaturated fatty acids ratio	LPA PLG LPAL2	7.96e-05	51	48	3	EFO_0022302
Disease	cholesterol to total lipids in small HDL percentage	LPA PLG LPAL2	7.96e-05	51	48	3	EFO_0022240
Disease	triglycerides in HDL measurement	LPA PLG LPAL2	8.94e-05	53	48	3	EFO_0022317
Disease	free cholesterol to total lipids in small LDL percentage	LPA PLG LPAL2	8.94e-05	53	48	3	EFO_0022286
Disease	triglycerides in medium HDL measurement	LPA PLG LPAL2	9.45e-05	54	48	3	EFO_0022321
Disease	triglycerides to total lipids in medium HDL percentage	LPA PLG LPAL2	1.05e-04	56	48	3	EFO_0022333
Disease	free cholesterol to total lipids in large HDL percentage	LPA PLG LPAL2	1.05e-04	56	48	3	EFO_0022279
Disease	cholesteryl esters to total lipids in medium HDL percentage	LPA PLG LPAL2	1.05e-04	56	48	3	EFO_0022251
Disease	very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	ASGR1 LPA HELZ2 PLG LPAL2	1.09e-04	291	48	5	EFO_0008317, EFO_0020946
Disease	low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	ASGR1 LPA PLG LPAL2	1.13e-04	153	48	4	EFO_0004611, EFO_0020946
Disease	low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio	ASGR1 LPA PLG LPAL2	1.13e-04	153	48	4	EFO_0004611, EFO_0020944
Disease	generalized epilepsy with febrile seizures plus 2 (implicated_via_orthology)	SCN2A SCN4A	1.16e-04	10	48	2	DOID:0111294 (implicated_via_orthology)
Disease	Dravet syndrome (implicated_via_orthology)	SCN2A SCN4A	1.16e-04	10	48	2	DOID:0080422 (implicated_via_orthology)
Disease	low density lipoprotein particle size measurement	LPA PLG LPAL2	1.17e-04	58	48	3	EFO_0008593
Disease	triglycerides to total lipids in small LDL percentage	LPA PLG LPAL2	1.23e-04	59	48	3	EFO_0022337
Disease	triglycerides to total lipids in large HDL percentage	LPA PLG LPAL2	1.30e-04	60	48	3	EFO_0022330
Disease	cholesterol to total lipids in medium HDL percentage	LPA PLG LPAL2	1.30e-04	60	48	3	EFO_0022237
Disease	free cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement	ASGR1 LPA SBF2 PLG LPAL2	1.32e-04	303	48	5	EFO_0004612, EFO_0020945
Disease	triglycerides in small VLDL measurement	LPA PLG LPAL2	1.36e-04	61	48	3	EFO_0022145
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	ASGR1 LPA PLG	1.36e-04	61	48	3	EFO_0008317, EFO_0008596, EFO_0020946
Disease	triglycerides to total lipids in very large HDL percentage	LPA PLG LPAL2	1.43e-04	62	48	3	EFO_0022339
Disease	triglycerides in small HDL measurement	LPA PLG LPAL2	1.43e-04	62	48	3	EFO_0022158
Disease	phospholipids in large VLDL measurement	LPA PLG LPAL2	1.43e-04	62	48	3	EFO_0022169
Disease	free cholesterol in very large HDL measurement	LPA PLG LPAL2	1.43e-04	62	48	3	EFO_0022273
Disease	parental longevity	LPA BEND3 PLG LPAL2 GRM5 BRAP	1.44e-04	494	48	6	EFO_0007796
Disease	triglycerides to total lipids in medium VLDL percentage	LPA PLG LPAL2	1.50e-04	63	48	3	EFO_0022335
Disease	cholesterol to total lipids in medium VLDL percentage	LPA PLG LPAL2	1.50e-04	63	48	3	EFO_0022239
Disease	free cholesterol to total lipids in medium LDL percentage	LPA PLG LPAL2	1.50e-04	63	48	3	EFO_0022283
Disease	triglyceride measurement, low density lipoprotein cholesterol measurement	ASGR1 LPA PLG LPAL2	1.55e-04	166	48	4	EFO_0004530, EFO_0004611
Disease	cholesteryl esters to total lipids in medium VLDL percentage	LPA PLG LPAL2	1.57e-04	64	48	3	EFO_0022253
Disease	triglycerides in small LDL measurement	LPA PLG LPAL2	1.64e-04	65	48	3	EFO_0022323
Disease	generalized epilepsy with febrile seizures plus (implicated_via_orthology)	SCN2A SCN4A	1.69e-04	12	48	2	DOID:0060170 (implicated_via_orthology)
Disease	high density lipoprotein particle size measurement	ASGR1 LPA PLG LPAL2	1.70e-04	170	48	4	EFO_0008592
Disease	phospholipid measurement, high density lipoprotein cholesterol measurement	ASGR1 LPA SBF2 PLG LPAL2	1.72e-04	321	48	5	EFO_0004612, EFO_0004639
Disease	cholesterol to total lipids in very small VLDL percentage	LPA PLG LPAL2	1.80e-04	67	48	3	EFO_0022245
Disease	triglycerides to phosphoglycerides ratio	LPA PLG LPAL2	1.88e-04	68	48	3	EFO_0022327
Disease	free cholesterol in large VLDL measurement	LPA PLG LPAL2	1.88e-04	68	48	3	EFO_0022265
Disease	triglycerides to total lipids in very small VLDL percentage	LPA PLG LPAL2	1.96e-04	69	48	3	EFO_0022341
Disease	cholesterol in very large HDL measurement	LPA PLG LPAL2	1.96e-04	69	48	3	EFO_0022229
Disease	triglycerides to total lipids in small HDL percentage	LPA PLG LPAL2	2.23e-04	72	48	3	EFO_0022336
Disease	urokinase plasminogen activator surface receptor measurement	ASGR1 LY75	2.33e-04	14	48	2	EFO_0010932
Disease	free cholesterol to total lipids in large LDL percentage	LPA PLG LPAL2	2.41e-04	74	48	3	EFO_0022280
Disease	free cholesterol to total lipids in small VLDL percentage	LPA PLG LPAL2	2.51e-04	75	48	3	EFO_0022287
Disease	triglycerides to total lipids in chylomicrons and extremely large VLDL percentage	LPA LPAL2	2.68e-04	15	48	2	EFO_0022328
Disease	monounsaturated fatty acids; 16:1, 18:1 measurement	LPA PLG LPAL2	2.82e-04	78	48	3	EFO_0022187
Disease	cholesterol to total lipids in chylomicrons and extremely large VLDL percentage	LPA LPAL2	3.47e-04	17	48	2	EFO_0022232
Disease	triglycerides:total lipids ratio, high density lipoprotein cholesterol measurement	ASGR1 LPA PLG LPAL2	3.53e-04	206	48	4	EFO_0004612, EFO_0020947
Disease	free cholesterol measurement, very low density lipoprotein cholesterol measurement	ASGR1 LPA PLG LPAL2	4.15e-04	215	48	4	EFO_0008317, EFO_0008591
Disease	very low density lipoprotein cholesterol measurement, lipid measurement	ASGR1 LPA PLG LPAL2	4.52e-04	220	48	4	EFO_0004529, EFO_0008317
Disease	very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio	LPA HELZ2 PLG LPAL2	4.68e-04	222	48	4	EFO_0008317, EFO_0020943
Disease	energy expenditure measurement	KCNC1 THSD7B	4.83e-04	20	48	2	EFO_0008005
Disease	triglyceride measurement, very low density lipoprotein cholesterol measurement	ASGR1 LPA PLG LPAL2	4.84e-04	224	48	4	EFO_0004530, EFO_0008317
Disease	total cholesterol measurement, very low density lipoprotein cholesterol measurement	ASGR1 LPA PLG LPAL2	4.84e-04	224	48	4	EFO_0004574, EFO_0008317
Disease	albuminuria	LPA SBF2 MAPKBP1	4.88e-04	94	48	3	EFO_0004285
Disease	cholesteryl ester measurement, very low density lipoprotein cholesterol measurement	ASGR1 LPA PLG LPAL2	4.92e-04	225	48	4	EFO_0008317, EFO_0010351
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, lipid measurement	LPA PLG LPAL2	5.03e-04	95	48	3	EFO_0004529, EFO_0008317, EFO_0008596
Disease	phospholipids:total lipids ratio	ASGR1 LPA PLG LPAL2	5.09e-04	227	48	4	EFO_0020946
Disease	chylomicron measurement, triglyceride measurement, very low density lipoprotein cholesterol measurement	LPA PLG LPAL2	5.19e-04	96	48	3	EFO_0004530, EFO_0008317, EFO_0008596
Disease	very low density lipoprotein cholesterol measurement, phospholipid measurement	ASGR1 LPA PLG LPAL2	5.26e-04	229	48	4	EFO_0004639, EFO_0008317
Disease	stroke, coronary artery disease	LPA BRAP	5.34e-04	21	48	2	EFO_0000712, EFO_0001645
Disease	Deep Vein Thrombosis	LPA PLG	5.34e-04	21	48	2	C0149871
Disease	free cholesterol to total lipids in chylomicrons and extremely large VLDL percentage	LPA LPAL2	5.34e-04	21	48	2	EFO_0022277
Disease	cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage	LPA LPAL2	5.34e-04	21	48	2	EFO_0022246
Disease	docosahexaenoic acid to total fatty acids percentage	LPA LPAL2	5.34e-04	21	48	2	EFO_0022262
Disease	Venous Thrombosis	LPA PLG	5.34e-04	21	48	2	C0042487
Disease	very low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	ASGR1 LPA PLG LPAL2	6.17e-04	239	48	4	EFO_0008317, EFO_0020945
Disease	Epilepsy, Benign Psychomotor, Childhood	KCNC4 GRM5	6.41e-04	23	48	2	C0393672
Disease	Epilepsy, Lateral Temporal	KCNC4 GRM5	6.41e-04	23	48	2	C0393682
Disease	Uncinate Epilepsy	KCNC4 GRM5	6.41e-04	23	48	2	C0014558
Disease	Epilepsy, Temporal Lobe	KCNC4 GRM5	6.41e-04	23	48	2	C0014556
Disease	cholesteryl esters:total lipids ratio, high density lipoprotein cholesterol measurement	ASGR1 LPA PLG LPAL2	6.57e-04	243	48	4	EFO_0004612, EFO_0020944
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement	LPA PLG LPAL2	6.93e-04	106	48	3	EFO_0008317, EFO_0008596
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, phospholipid measurement	LPA PLG LPAL2	7.51e-04	109	48	3	EFO_0004639, EFO_0008317, EFO_0008596
Disease	large artery stroke, coronary artery disease	LPA BRAP	7.59e-04	25	48	2	EFO_0001645, EFO_0005524
Disease	cholesteryl ester measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement	LPA PLG LPAL2	7.72e-04	110	48	3	EFO_0008317, EFO_0008596, EFO_0010351
Disease	free cholesterol measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement	LPA PLG LPAL2	7.72e-04	110	48	3	EFO_0008317, EFO_0008591, EFO_0008596
Disease	chylomicron measurement, total cholesterol measurement, very low density lipoprotein cholesterol measurement	LPA PLG LPAL2	7.72e-04	110	48	3	EFO_0004574, EFO_0008317, EFO_0008596
Disease	lipoprotein A measurement	LPA PLG LPAL2	8.13e-04	112	48	3	EFO_0006925
Disease	very low density lipoprotein cholesterol measurement	ASGR1 LPA PLG LPAL2	8.45e-04	260	48	4	EFO_0008317

Protein segments in the cluster

Peptide	Gene	Start	Entry
DDVCQRPYRWVCETE	ASGR1	266	P07306
CLQRWDDTTCPVCRY	BRAP	291	Q7Z569
CAAELVCKEWYRVTS	BTRC	206	Q9Y297
IFDCTECYDPVTKQW	IPP	356	Q9Y573
ECAASWLQRTPVVYC	INTS15	131	Q96N11
VWHYECIPSIDERCR	BEND3	796	Q5T5X7
LSVEEQKWPCARCTF	CAPN15	41	O75808
TPEWLEECFRCQKFI	PAXIP1	926	Q6ZW49
QAWCDTCEKYQPTIQ	PAN2	716	Q504Q3
CVEQGRTKCEEYWPS	PTPRJ	1141	Q12913
CWTCTPCKENEYVFD	GRM5	531	P41594
EIDCDVPTCGQWLKY	LRP12	251	Q9Y561
RRTVWPCYDDVSCTQ	SBF2	1621	Q86WG5
CPKQTWCAEANRIYD	MUC19	8266	Q7Z5P9
YCVWVVSATEELQPC	MEGF8	1301	Q7Z7M0
CIKPVYGWIVADDCD	LY75	46	O60449
CDPDWSRVNCSVYVQ	PLPP2	131	O43688
YFDWVKPQSSCCRVD	NPC1	946	O15118
IDETDVEPCCWMTYR	KCNC1	96	P48547
EWVLEPYCPSTCQRS	C19orf71	186	A6NCJ1
RWEYCNLTQCPVTES	LPA	1236	P08519
RWEYCNLTRCPVTES	LPA	1456	P08519
CVWSVEVYPEVKDSN	MAPKBP1	391	O60336
SLYRDCQKTCWEPAS	KRTAP13-4	46	Q3LI77
KVQCYDQCENRWTVP	ENC1	461	O14682
RCKTLDCYDPTLDVW	ENC1	551	O14682
RDVDEYACVWEPFCA	HELZ2	1936	Q9BYK8
CEFQCDITPWESKRR	ITGBL1	216	O95965
DYVIKWCNSSRSEPC	LIFR	656	P42702
DICIQWRTPDYCSLS	OTOGL	1791	Q3ZCN5
DCIWYCIPAEEENKL	JARID2	946	Q92833
QRCVYLEDCVEPAVW	OTOG	1456	Q6ZRI0
CIPDSTIPQEDYRCW	PKDCC	411	Q504Y2
EACVQRWPCLYVDIS	SCN4A	996	P35499
TDPNVRWEYCNLTRC	LPAL2	91	Q16609
AIPNQDYECWKDDSC	SSMEM1	21	Q8WWF3
PCVDSYSELCTWKLE	TAF2	191	Q6P1X5
QVRWEYCKIPSCDSS	PLG	341	P00747
ELTLWVDPCEVCCRY	BTG3	91	Q14201
EMTIWVDPFEVCCRY	BTG4	91	Q9NY30
TWRCEVCDYETNVAR	ZFHX4	766	Q86UP3
EELEESRQKCPPCWY	SCN2A	716	Q99250
FSDTAKCPVCRWQIE	NEURL3	231	Q96EH8
WFEVYNATRVPDSCC	TSPAN4	156	O14817
VDPQYTWRAICNLCE	ZBED6	141	P86452
NFQRVEEYCEKVWCT	SEMA3E	721	O15041
ERECEDVSLCPVYRW	THSD7B	786	Q9C0I4
PWNFISERSCIYEEK	ZNF354B	116	Q96LW1
KVDRTVYQFCSPSCW	ZMYM3	561	Q14202
KPTWRCEVCDYETNV	ZFHX3	801	Q15911
YCSTEIRWICQKELT	KLRB1	201	Q12918
DETDVEPCCWMTYRQ	KCNC4	136	Q03721